Chuck Royce's HAE Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 71,475 shares of Haemonetics Corporation (HAE) worth $5.73 M, representing 0.06% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2021, adding 382,812 shares. Largest reduction occurred in Q4 2025, reducing 629,767 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -629,767 | Reduce 89.81% | 71,475 | $80.15 |
| Q3 2025 | -569,815 | Reduce 44.83% | 701,242 | $48.74 |
| Q2 2025 | +109,761 | Add 9.45% | 1.27 M | $74.61 |
| Q1 2025 | +8,028 | Add 0.70% | 1.16 M | $63.55 |
| Q4 2024 | -57,278 | Reduce 4.73% | 1.15 M | $78.08 |
| Q3 2024 | +30,868 | Add 2.62% | 1.21 M | $80.38 |
| Q2 2024 | -86,936 | Reduce 6.86% | 1.18 M | $82.73 |
| Q1 2024 | +300,259 | Add 31.07% | 1.27 M | $85.35 |
| Q4 2023 | +18,805 | Add 1.98% | 966,355 | $85.51 |
| Q3 2023 | +41,258 | Add 4.55% | 947,550 | $89.58 |
| Q2 2023 | +62,538 | Add 7.41% | 906,292 | $85.14 |
| Q1 2023 | +18,292 | Add 2.22% | 843,754 | $82.75 |
| Q4 2022 | -49,346 | Reduce 5.64% | 825,462 | $78.65 |
| Q3 2022 | +33,223 | Add 3.95% | 874,808 | $74.03 |
| Q2 2022 | +84,341 | Add 11.14% | 841,585 | $65.18 |
| Q1 2022 | +49,136 | Add 6.94% | 757,244 | $63.22 |
| Q4 2021 | -276,250 | Reduce 28.06% | 708,108 | $53.04 |
| Q3 2021 | +382,812 | Add 63.64% | 984,358 | $70.59 |
| Q2 2021 | +132,961 | Add 28.38% | 601,546 | $66.64 |
| Q1 2021 | -130,171 | Reduce 21.74% | 468,585 | $111.01 |
| Q4 2020 | +15,148 | Add 2.60% | 598,756 | $118.75 |
| Q3 2020 | +90,415 | Add 18.33% | 583,608 | $87.25 |
| Q2 2020 | +116,588 | Add 30.96% | 493,193 | $89.56 |
| Q1 2020 | +346,436 | Add 1148.32% | 376,605 | $99.66 |
| Q4 2019 | +30,169 | New Buy | 30,169 | $114.89 |
| Q3 2018 | -19,300 | Sold Out | 0 | $0.00 |
| Q2 2018 | -700 | Reduce 3.50% | 19,300 | $89.69 |
| Q1 2018 | +19,792 | Add 9515.38% | 20,000 | $73.15 |
| Q4 2017 | -41 | Reduce 16.47% | 208 | $57.69 |
| Q3 2017 | +249 | New Buy | 249 | $44.18 |
| Q4 2013 | -224,100 | Sold Out | 0 | $0.00 |
| Q3 2013 | -103,900 | Reduce 31.68% | 224,100 | $39.88 |
| Q2 2013 | +328,000 | Add 0.00% | 328,000 | $41.35 |
Chuck Royce's Haemonetics Corporation Investment FAQs
Chuck Royce first purchased Haemonetics Corporation (HAE) in Q2 2013, acquiring 328,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Haemonetics Corporation (HAE) for 33 quarters since Q2 2013.
Chuck Royce's largest addition to Haemonetics Corporation (HAE) was in Q3 2021, adding 984,358 shares worth $69.49 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 71,475 shares of Haemonetics Corporation (HAE), valued at approximately $5.73 M.
As of the Q4 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.06% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Haemonetics Corporation (HAE) was 1,271,057 shares, as reported at the end of Q2 2025.